Current treatment for ovarian cancer - PubMed (original) (raw)
Review
Current treatment for ovarian cancer
G H Eltabbakh et al. Expert Opin Pharmacother. 2001 Jan.
Abstract
Ovarian cancer is the most lethal gynaecologic malignancy. Epithelial ovarian cancer (EOC) constitutes approximately 90% of cases of ovarian cancer and 70% of the patients with EOC present in advanced stage. Treatment of EOC usually consists of cytoreductive surgery which includes total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), omentectomy and lymphadenectomy followed by adjuvant chemotherapy. Current adjuvant chemotherapy includes paclitaxel and either cisplatin or carboplatin given every 3 weeks for six cycles. The combination paclitaxel and platinum chemotherapy achieves clinical response in approximately 80% of patients. However, most patients will have tumour recurrence within 3 years following treatment. Patients with platinum-sensitive tumours can be re-treated with platinum and/or paclitaxel. Those with platinum-resistant tumours have poor prognosis and treatment is palliative. Options of treatment in these patients include topotecan, doxil, gemcitabine, etoposide, or enrolment in clinical trials. Future research needs to focus on the role of cytoreductive surgery, second-look surgery, consolidation chemotherapy, development of new chemotherapeutic agents, chemoresistance modulators, as well as new approaches to the treatment of women with ovarian cancer.
Similar articles
- A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. Högberg T, et al. Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420. Acta Oncol. 2001. PMID: 11441940 Review. - Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR, Zeeneldin AA, Helal AM, Ismail YM, Elsayed AM, Elbassuiony MA, Moneer MM. Nassar HR, et al. Asian Pac J Cancer Prev. 2015;16(16):7237-42. doi: 10.7314/apjcp.2015.16.16.7237. Asian Pac J Cancer Prev. 2015. PMID: 26514517 - Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Colombo N, et al. Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review. - Medical treatment of epithelial ovarian cancer.
González-Martín AJ. González-Martín AJ. Expert Rev Anticancer Ther. 2004 Dec;4(6):1125-43. doi: 10.1586/14737140.4.6.1125. Expert Rev Anticancer Ther. 2004. PMID: 15606338 Review. - Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE. Roland PY, et al. Gynecol Oncol. 1998 Feb;68(2):178-82. doi: 10.1006/gyno.1997.4909. Gynecol Oncol. 1998. PMID: 9514799
Cited by
- An integrative approach to identifying cancer chemoresistance-associated pathways.
Chao SY, Chiang JH, Huang AM, Chang WS. Chao SY, et al. BMC Med Genomics. 2011 Mar 24;4:23. doi: 10.1186/1755-8794-4-23. BMC Med Genomics. 2011. PMID: 21429228 Free PMC article. - Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model.
Hopkins ML, Coyle D, Le T, Fung MF, Wells G. Hopkins ML, et al. Curr Oncol. 2007 Oct;14(5):167-72. doi: 10.3747/co.2007.144. Curr Oncol. 2007. PMID: 17938699 Free PMC article. - Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer.
Choi CH, Kang TH, Song JS, Kim YS, Chung EJ, Ylaya K, Kim S, Koh SS, Chung JY, Kim JH, Hewitt SM. Choi CH, et al. Sci Rep. 2018 Aug 15;8(1):12161. doi: 10.1038/s41598-018-30582-8. Sci Rep. 2018. PMID: 30111860 Free PMC article. - Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation?
Marcelis CL, van der Putten HW, Tops C, Lutgens LC, Moog U. Marcelis CL, et al. Fam Cancer. 2001;1(2):107-9. doi: 10.1023/a:1013865323890. Fam Cancer. 2001. PMID: 14574006 - Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines.
Shun MC, Yu W, Park SK, Sanders BG, Kline K. Shun MC, et al. J Oncol. 2010;2010:824571. doi: 10.1155/2010/824571. Epub 2010 Mar 4. J Oncol. 2010. PMID: 20224651 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical